PET/CT Imaging for Kidney Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging technique called PET/CT with a special tracer, [18F] PSMA-1007, to better detect the spread of kidney cancer. The goal is to determine if this method can identify cancer that other scans might miss, potentially altering treatment approaches. Individuals with kidney cancer that includes a clear cell component and who have already undergone standard scans might be suitable for this study. As an Early Phase 1 trial, the study aims to understand how this new imaging technique functions in people, offering participants the opportunity to be among the first to benefit from potentially groundbreaking diagnostic advancements.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this imaging technique is safe for kidney cancer patients?
Research has shown that [18F] PSMA-1007 PET/CT is under study for its potential to image cancer. One study compared it to another imaging method and found it similarly effective in detecting cancer spread, suggesting it may be useful in identifying cancer's spread in the body.
However, specific safety information from these studies remains limited. As this trial is in its early stages, the primary focus is on assessing the treatment's safety. Early trials typically involve small groups to evaluate how well participants tolerate the treatment. While some information about how [18F] PSMA-1007 functions is available, further research is necessary to understand potential side effects. Participants should be aware that not all side effects may be known at this stage.12345Why are researchers excited about this trial?
Researchers are excited about [18F] PSMA-1007 PET/CT for kidney cancer because it offers a novel approach to imaging compared to traditional methods like CT or MRI scans. This treatment uses a specific radioactive tracer, [18F] PSMA-1007, which targets the prostate-specific membrane antigen (PSMA) often found in higher levels in certain cancer cells. This targeting allows for more precise imaging of cancerous tissues, potentially leading to better diagnosis and treatment planning. Unlike standard imaging techniques, which may struggle to distinguish between cancerous and non-cancerous tissues, [18F] PSMA-1007 PET/CT offers the promise of greater accuracy and clarity, paving the way for improved patient outcomes.
What evidence suggests that [18F] PSMA-1007 PET/CT is effective for staging kidney cancer?
Research has shown that [18F] PSMA-1007 PET/CT scans outperform traditional methods in detecting cancer spread. This scan excels at identifying metastatic kidney cancer compared to standard scans like CT or MRI. Studies have found that [18F] PSMA-1007 PET/CT can reveal hidden cancer spread, crucial for selecting the best treatment. It also more accurately determines the stage of prostate cancer, suggesting similar success for kidney cancer. Early evidence indicates that using [18F] PSMA-1007 PET/CT could help doctors make better treatment decisions by providing a clearer view of cancer spread. Participants in this trial will undergo the [18F] PSMA-1007 PET/CT scan to assess its effectiveness in detecting kidney cancer spread.16789
Who Is on the Research Team?
Melissa Huynh, MD
Principal Investigator
Western University
Are You a Good Fit for This Trial?
This trial is for individuals with metastatic clear cell renal cell carcinoma. It's designed to see if a new type of PET/CT scan can find hidden cancer spread better than current methods.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Baseline Assessment
Participants undergo baseline conventional imaging and [18F] PSMA-1007 PET/CT to identify metastatic lesions
Follow-up
Participants are monitored for changes in management based on imaging results
What Are the Treatments Tested in This Trial?
Interventions
- [18F] PSMA-1007 PET/CT
Find a Clinic Near You
Who Is Running the Clinical Trial?
Western University
Lead Sponsor